8-K: STAAR Surgical Reports Mixed Q3 Sales Amid China Headwinds

STAAR Surgical announced preliminary third-quarter 2025 net sales of $94.7 million, up 6.9% year-over-year, primarily boosted by a prior China shipment payment, while new orders from China declined.

Summary

• Preliminary net sales for the third quarter ended September 26, 2025, were $94.7 million, representing a 6.9% increase compared to $88.6 million in the prior year period.
• The reported net sales included $25.9 million related to a previously disclosed December 2024 ICL shipment to a China distributor, for which extended payment terms were fulfilled in Q3 2025.
• The year-over-year increase in preliminary net sales was primarily driven by the recognition of the December China Shipment payment and 7.7% growth in net sales outside China.
• New orders from distributors in China were lower during Q3 2025, partly due to leaner inventory management.
• For the nine months ended September 26, 2025, sales were lower than the prior year period as distributors in China reduced their inventory by approximately $80 million to $85 million instead of purchasing new product.
• As of September 26, 2025, China distributors maintained owned inventory at approximately six months, aligned to contractual levels.
• The financial information presented is unaudited and subject to adjustment during the company's quarterly review and finalization process.
• A Special Meeting of Stockholders is scheduled for October 23, 2025, to vote on the proposed Alcon merger.

Sentiment

Score: 4

Explanation: While headline net sales show growth, this is largely due to the recognition of a prior shipment. The underlying trend of lower new orders and significant inventory reduction by distributors in China for the nine-month period indicates considerable headwinds and masks a weaker operational performance in a key market. The pending merger adds uncertainty.

Positives

• Preliminary net sales increased by 6.9% year-over-year to $94.7 million for Q3 2025.
• The company successfully collected $25.9 million in Q3 2025 from a previously disclosed December 2024 China ICL shipment with extended payment terms.
• Net sales outside China demonstrated solid growth of 7.7%.

Negatives

• Lower new orders from distributors in China during Q3 2025, attributed to leaner inventory management, indicate underlying market weakness.
• Sales for the nine months ended September 26, 2025, were lower than the prior year due to China distributors reducing inventory by $80 million to $85 million, significantly impacting new product purchases.
• The reported 6.9% net sales growth for Q3 2025 was primarily driven by the recognition of a prior year's China shipment payment, masking a decline in new orders from the region.

Risks

• STAAR's ability to continue its growth and profitability trajectory, including as a result of a slowdown or disruption to the Chinese economy or new competition.
• Potential adjustments to preliminary net sales during the quarterly financial close process or independent registered public accounting firm's review.
• The occurrence of any event, change, or other circumstances that could lead to the termination of the Alcon merger agreement or cause delays in its consummation.
• Failure to obtain approval of the proposed transaction from STAAR's stockholders.
• Failure to obtain certain required regulatory approvals or satisfy any other closing conditions for the completion of the proposed transaction within expected timeframes or at all.
• Risks related to disruption of management's attention from STAAR's ongoing business operations due to the proposed transaction.
• The effect of the announcement of the proposed transaction on STAAR's ability to retain and hire key personnel and maintain relationships with its customers, suppliers, and others.
• The ability of STAAR to meet expectations regarding the timing and completion of the transaction.
• The outcome of any legal proceedings that may be instituted against STAAR related to the proposed transaction.
• The possibility that STAAR's stock price may decline significantly if the proposed transaction is not consummated.

Future Outlook

The company anticipates completing its quarterly review and finalizing financial statements for the quarter ended September 26, 2025, which will be filed in its Quarterly Report on Form 10-Q. A Special Meeting of Stockholders is scheduled for October 23, 2025, to vote on the proposed Alcon merger.

Management Comments

• STAAR is announcing its preliminary net sales results in advance of its quarterly earnings announcement to provide all stockholders with additional information regarding third quarter net sales performance and trends in advance of the STAAR Special Meeting of Stockholders scheduled for October 23, 2025, to vote on the Alcon merger proposal.

Industry Context

STAAR Surgical, a global leader in phakic IOLs with its EVO ICL product line, operates in the ophthalmic surgery market. The announcement of preliminary sales results, particularly with significant dynamics in the China market and the pending merger with Alcon, highlights the competitive and evolving landscape for vision correction solutions. The merger proposal with Alcon, a major player in eye care, signifies potential consolidation and strategic shifts within the industry.

Corporate Governance

Legal Proceedings

• The company identifies 'the outcome of any legal proceedings that may be instituted against STAAR related to the proposed transaction' as a risk factor.

Stakeholder Impact

• Shareholders are directly impacted by the preliminary sales results and the upcoming vote on the Alcon merger, which could significantly alter the company's valuation and future. Proxy solicitor contact information is provided for voting assistance.
• Customers, particularly distributors in China, are impacting the company's sales performance through their inventory management decisions and reduced new orders.
• Employees face potential risks related to management's attention being diverted and the ability to retain and hire key personnel due to the proposed merger.
• Suppliers' relationships could be affected by the merger announcement and potential operational changes.

Next Steps

• Completion of the company's quarterly review and finalization of financial statements.
• Filing of the Quarterly Report on Form 10-Q for the quarter ended September 26, 2025.
• Special Meeting of Stockholders on October 23, 2025, to vote on the Alcon merger proposal.

Key Dates

Recommendation

The preliminary Q3 2025 net sales, while showing a headline increase, are significantly boosted by the recognition of a prior China shipment. The underlying trend of lower new orders from China and a substantial inventory reduction by distributors in that region for the year-to-date period indicates significant operational headwinds. The pending Alcon merger introduces both potential upside and considerable integration and execution risks. Given these mixed signals and the uncertainty surrounding the merger, a 'hold' recommendation is prudent until more clarity emerges on the merger's outcome and the company's ability to navigate the challenges in the China market.

Keywords

STAAR Surgical, STAA, preliminary sales, net sales, Q3 2025, Implantable Collamer Lenses, EVO ICL, vision correction, China market, inventory management, Alcon merger, ophthalmic surgery, phakic IOLs